• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Issues Revised Guidelines for Legal Agent Responsibilities for Adverse Events

NMPA Issues Revised Guidelines for Legal Agent Responsibilities for Adverse Events

Tuesday, 12 May 2020 / Published in Medical Device

NMPA Issues Revised Guidelines for Legal Agent Responsibilities for Adverse Events

On 10.04.2020, the NMPA (National Medical Products Administration) made the announcement No.25-2020 to provide guidance to NMPA Legal Agents on the timescales for monitoring and reporting medical device adverse events.

A summary of the NMPA Legal Agent responsibilities for monitoring medical device adverse events: 

– A well-established monitoring system for medical device adverse events

– Based on the business structure, an appropriate percentage of staffs should be assigned to monitor medical device adverse events

– Collect, report, investigate, analyse and evaluate medical device adverse events in a proactive manner

– Take effective measures for risk control and inform the public in a timely manner

– Continue to conduct research on the safety of already registered medical devices

– Carry out risk assessments and key monitoring work as required and submit relevant reports

– Cooperate with the MPAs in carrying out medical device adverse event monitoring related work

– The NMPA Legal Agent shall establish an information transmission mechanism with overseas manufacturers to promptly exchange information on the adverse event monitoring and re-evaluation of medical devices

– The NMPA Legal Agent shall be registered as an account user of the National Medical Device Adverse Event Monitoring Information System to directly report any adverse events when required

– Responsible for the maintenance of account user and product registration information in a timely manner

– For any changes made to the product registration information, it should be immediately updated in the system

Timescale for adverse events reporting

We note that this announcement should be read together with the NMPA’s new requirements for periodic risk assessment released on 6 May, and further illustrates the NMPA’s increasing emphasis on post-market surveillance.

By Jacky Li. Contact Cisema to learn more.

What you can read next

china yy standards
China YY Standards 2022 – New NMPA Updates Announced
Free Trade Zone
Hainan Pilot Zone (Boao Lecheng)
Importing Drugs and Medical Devices for Urgent Clinical Use in GBA

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.